Modulation of C-reactive protein and plasma omega-6 fatty acid levels by phospholipase A2 gene polymorphisms following a 6-week supplementation with fish oil

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 102-103, Issue , 2015, Pages 37-45

  Tremblay, B L ^a   Rudkowska, I ^a,b   Couture, P ^a   Lemieux, S ^a   Julien, P ^b   Vohl, M C ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

C reactive protein; Gene diet interaction; Inflammation; Omega 3 fatty acid; Omega 6 fatty acid; Phospholipase A2

Indexed keywords

C REACTIVE PROTEIN; FISH OIL; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PHOSPHOLIPASE A2; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE A2 GROUP IV; PHOSPHOLIPASE A2 GROUP VI; PHOSPHOLIPID; PLA2G4A PROTEIN, HUMAN; PLA2G6 PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL TRIAL; FATTY ACID BLOOD LEVEL; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; LIPID DIET; MALE; NUTRITIONAL VALUE; PHOSPHOLIPASE A2 GENE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; ADOLESCENT; ANTAGONISTS AND INHIBITORS; BLOOD; BODY MASS; CHEMISTRY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIETARY SUPPLEMENT; GENETIC ASSOCIATION STUDY; GENETICS; METABOLISM; MIDDLE AGED; NUTRIGENOMICS; OBESITY; PROCEDURES; QUEBEC; SEXUAL DEVELOPMENT; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BODY MASS INDEX; C-REACTIVE PROTEIN; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-6; FEMALE; FISH OILS; GENETIC ASSOCIATION STUDIES; GROUP IV PHOSPHOLIPASES A2; GROUP VI PHOSPHOLIPASES A2; HUMANS; MALE; MIDDLE AGED; NUTRIGENOMICS; OVERWEIGHT; PHOSPHOLIPIDS; POLYMORPHISM, SINGLE NUCLEOTIDE; QUEBEC; SEX CHARACTERISTICS; YOUNG ADULT;

EID: 84946746834     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2015.10.002     Document Type: Article

References (64)

1. Albers J.J., Warnick G.R., Wiebe D., et al. Multi-laboratory comparison of three heparin-Mn2+ precipitation procedures for estimating cholesterol in high-density lipoprotein. Clin. Chem. 1978, 24:853-856.
2. Mozaffarian D., Rimm E.B. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA 2006, 296:1885-1899.
3. Wang C., Harris W.S., Chung M., et al. n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am. J. Clin. Nutr. 2006, 84:5-17.
4. Simopoulos A.P. Omega-3 fatty acids in inflammation and autoimmune diseases. J. Am. Coll. Nutr. 2002, 21:495-505.
5. Harris W.S. n-3 fatty acids and serum lipoproteins: human studies. Am. J. Clin. Nutr. 1997, 65:1645S-1654S.
6. Farzaneh-Far R., Harris W.S., Garg S., Na B., Whooley M.A. Inverse association of erythrocyte n-3 fatty acid levels with inflammatory biomarkers in patients with stable coronary artery disease: the heart and soul study. Atherosclerosis 2009, 205:538-543.
7. Kalogeropoulos N., Panagiotakos D.B., Pitsavos C., et al. Unsaturated fatty acids are inversely associated and n-6/n-3 ratios are positively related to inflammation and coagulation markers in plasma of apparently healthy adults. Clin. Chim. Acta 2010, 411:584-591.
8. Lopez-Garcia E., Schulze M.B., Fung T.T., et al. Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction. Am. J. Clin. Nutr. 2004, 80:1029-1035.
9. Tayyebi-Khosroshahi H., Houshyar J., Dehgan-Hesari R., et al. Effect of treatment with omega-3 fatty acids on C-reactive protein and tumor necrosis factor-alfa in hemodialysis patients. Saudi J. Kidney Dis. Transplant. 2012, 23:500-506.
10. Geelen A., Brouwer I.A., Schouten E.G., Kluft C., Katan M.B., Zock P.L. Intake of n-3 fatty acids from fish does not lower serum concentrations of C-reactive protein in healthy subjects. Eur. J. Clin. Nutr. 2004, 58:1440-1442.
11. Madsen T., Christensen J.H., Blom M., Schmidt E.B. The effect of dietary n-3 fatty acids on serum concentrations of C-reactive protein: a dose-response study. Br. J. Nutr. 2003, 89:517-522.
12. Pischon T., Hankinson S.E., Hotamisligil G.S., Rifai N., Willett W.C., Rimm E.B. Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation 2003, 108:155-160.
13. Skulas-Ray A.C., Kris-Etherton P.M., Harris W.S., Vanden Heuvel J.P., Wagner P.R., West S.G. Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia. Am. J. Clin. Nutr. 2011, 93:243-252.
14. Calder P.C. Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. Biochim. Biophys. Acta 2015, 1851:469-484.
15. Calder P.C. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology?. Br. J. Clin. Pharmacol. 2013, 75:645-662.
16. Dennis E.A., Cao J., Hsu Y.H., Magrioti V., Kokotos G. Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem. Rev. 2011, 111:6130-6185.
17. Hui D.Y. Phospholipase A (2) enzymes in metabolic and cardiovascular diseases. Curr. Opin. Lipidol. 2012, 23:235-240.
18. Hartiala J., Li D., Conti D.V., et al. Genetic contribution of the leukotriene pathway to coronary artery disease. Hum. Genet. 2011, 129:617-627.
19. Hartiala J., Gilliam E., Vikman S., Campos H., Allayee H. Association of PLA2G4A with myocardial infarction is modulated by dietary PUFAs. Am. J. Clin. Nutr. 2012, 95:959-965.
20. Rudkowska I., Paradis A.M., Thifault E., et al. Differences in metabolomic and transcriptomic profiles between responders and non-responders to an n-3 polyunsaturated fatty acids (PUFAs) supplementation. Genes Nutr. 2013, 8:411-423.
21. Six D.A., Dennis E.A. The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. Biochim. Biophys. Acta 2000, 1488:1-19.
22. Health Canada, Canada[U+05F3]s Food Guide, 2011.
23. Callaway C.W., Chumlea W.C., Bouchard C., et al. Standardization of Anthropomeric Measurements 1988, 39-80. Human Kinetics Publishers, Champaign, IR, USA.
24. McNamara J.R., Schaefer E.J. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin. Chim. Acta 1987, 166:1-8.
25. Burstein M., Samaille J. On a rapid determination of the cholesterol bound to the serum alpha- and beta-lipoproteins. Clin. Chim. Acta 1960, 5:609.
26. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972, 18:499-502.
27. Pirro M., Bergeron J., Dagenais G.R., et al. Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men. Arch. Intern. Med. 2001, 161:2474-2480.
28. Shaikh N.A., Downar E. Time course of changes in porcine myocardial phospholipid levels during ischemia. A reassessment of the lysolipid hypothesis. Circ. Res. 1981, 49:316-325.
29. Kroger E., Verreault R., Carmichael P.H., et al. Omega-3 fatty acids and risk of dementia: the Canadian study of health and aging. Am. J. Clin. Nutr. 2009, 90:184-192.
30. Patel P.S., Sharp S.J., Jansen E., et al. Fatty acids measured in plasma and erythrocyte-membrane phospholipids and derived by food-frequency questionnaire and the risk of new-onset type 2 diabetes: a pilot study in the European prospective investigation into cancer and nutrition (EPIC)-Norfolk cohort. Am. J. Clin. Nutr. 2010, 92:1214-1222.
31. Livak K.J. Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet. Anal. 1999, 14:143-149.
32. Thifault E., Cormier H., Bouchard-Mercier A., et al. Effects of age, sex, body mass index and APOE genotype on cardiovascular biomarker response to an n-3 polyunsaturated fatty acid supplementation. J. Nutrigenet. Nutrigenomics 2013, 6:73-82.
33. Jellema A., Plat J., Mensink R.P. Weight reduction, but not a moderate intake of fish oil, lowers concentrations of inflammatory markers and PAI-1 antigen in obese men during the fasting and postprandial state. Eur. J. Clin. Investig. 2004, 34:766-773.
34. Flock M.R., Skulas-Ray A.C., Harris W.S., Gaugler T.L., Fleming J.A., Kris-Etherton P.M. Effects of supplemental long-chain omega-3 fatty acids and erythrocyte membrane fatty acid content on circulating inflammatory markers in a randomized controlled trial of healthy adults. Prostaglandins Leukot. Essent. Fatty Acids 2014, 91:161-168.
35. Calder P.C., Ahluwalia N., Brouns F., et al. Dietary factors and low-grade inflammation in relation to overweight and obesity. Br. J. Nutr. 2011, 106(Suppl 3):S5-78.
36. Grimble R.F., Howell W.M., O[U+05F3]Reilly G., et al. The ability of fish oil to suppress tumor necrosis factor alpha production by peripheral blood mononuclear cells in healthy men is associated with polymorphisms in genes that influence tumor necrosis factor alpha production. Am. J. Clin. Nutr. 2002, 76:454-459.
37. Joffe Y.T., Collins M., Goedecke J.H. The relationship between dietary fatty acids and inflammatory genes on the obese phenotype and serum lipids. Nutrients 2013, 5:1672-1705.
38. Stryjecki C., Mutch D.M. Fatty acid-gene interactions, adipokines and obesity. Eur. J. Clin. Nutr. 2011, 65:285-297.
39. Ridker P.M., Silvertown J.D. Inflammation, C-reactive protein, and atherothrombosis. J. Periodontol. 2008, 79:1544-1551.
40. Madsen T., Skou H.A., Hansen V.E., et al. C-reactive protein, dietary n-3 fatty acids, and the extent of coronary artery disease. Am. J. Cardiol. 2001, 88:1139-1142.
41. Fernandez-Real J.M., Broch M., Vendrell J., Ricart W. Insulin resistance, inflammation, and serum fatty acid composition. Diabetes Care 2003, 26:1362-1368.
42. Ferrucci L., Cherubini A., Bandinelli S., et al. Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. J. Clin. Endocrinol. Metab. 2006, 91:439-446.
43. Klein-Platat C., Drai J., Oujaa M., Schlienger J.L., Simon C. Plasma fatty acid composition is associated with the metabolic syndrome and low-grade inflammation in overweight adolescents. Am. J. Clin. Nutr. 2005, 82:1178-1184.
44. Petersson H., Basu S., Cederholm T., Riserus U. Serum fatty acid composition and indices of stearoyl-CoA desaturase activity are associated with systemic inflammation: longitudinal analyses in middle-aged men. Br. J. Nutr. 2008, 99:1186-1189.
45. Perreault M., Roke K., Badawi A., et al. Plasma levels of 14:0, 16:0, 16:1n-7, and 20:3n-6 are positively associated, but 18:0 and 18:2n-6 are inversely associated with markers of inflammation in young healthy adults. Lipids 2014, 49:255-263.
46. Wener M.H., Daum P.R., McQuillan G.M. The influence of age, sex, and race on the upper reference limit of serum C-reactive protein concentration. J. Rheumatol 2000, 27:2351-2359.
47. Wang T.J., Nam B.H., Wilson P.W., et al. Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham heart study. Arterioscler. Thromb. Vasc. Biol. 2002, 22:1662-1667.
48. McConnell J.P., Branum E.L., Ballman K.V., Lagerstedt S.A., Katzmann J.A., Jaffe A.S. Gender differences in C-reactive protein concentrations-confirmation with two sensitive methods. Clin. Chem. Lab. Med. 2002, 40:56-59.
49. Wong N.D., Pio J., Valencia R., Thakal G. Distribution of C-reactive protein and its relation to risk factors and coronary heart disease risk estimation in the national health and nutrition examination survey (NHANES) III. Prev. Cardiol. 2001, 4:109-114.
50. Ford E.S., Giles W.H., Mokdad A.H., Myers G.L. Distribution and correlates of C-reactive protein concentrations among adult US women. Clin. Chem. 2004, 50:574-581.
51. Khera A., McGuire D.K., Murphy S.A., et al. Race and gender differences in C-reactive protein levels. J. Am. Coll. Cardiol. 2005, 46:464-469.
52. Lakoski S.G., Cushman M., Criqui M., et al. Gender and C-reactive protein: data from the multiethnic study of atherosclerosis (MESA) cohort. Am. Heart J. 2006, 152:593-598.
53. Rexrode K.M., Pradhan A., Manson J.E., Buring J.E., Ridker P.M. Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann. Epidemiol. 2003, 13:674-682.
54. Ridker P.M., Hennekens C.H., Rifai N., Buring J.E., Manson J.E. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999, 100:713-716.
55. Kwok S., Canoy D., Ashton W.D., et al. Increased C-reactive protein levels in overweight and obese women taking exogenous hormones: the United Kingdom Women[U+05F3]s Heart Study (UKWHS). Clin. Endocrinol. 2009, 71:727-732.
56. Soska V., Fiala J., Nebeska K., Jarkovsky J., Hruba D. The atherogenic index of plasma is increased by hormonal contraception. Scand. J. Clin. Lab. Investig. 2011, 71:94-100.
57. Dreon D.M., Slavin J.L., Phinney S.D. Oral contraceptive use and increased plasma concentration of C-reactive protein. Life Sci 2003, 73:1245-1252.
58. Kluft C., Leuven J.A., Helmerhorst F.M., Krans H.M. Pro-inflammatory effects of oestrogens during use of oral contraceptives and hormone replacement treatment. Vasc. Pharmacol 2002, 39:149-154.
59. Cartier A., Cote M., Lemieux I., et al. Sex differences in inflammatory markers: what is the contribution of visceral adiposity?. Am. J. Clin. Nutr. 2009, 89:1307-1314.
60. Farooqui A.A., Horrocks L.A., Farooqui T. Modulation of inflammation in brain: a matter of fat. J. Neurochem. 2007, 101:577-599.
61. Cathcart M.K. Signal-activated phospholipase regulation of leukocyte chemotaxis. J Lipid Res 2009, 50(Suppl):S231-S236.
62. Winstead M.V., Balsinde J., Dennis E.A. Calcium-independent phospholipase A(2): structure and function. Biochim. Biophys. Acta 2000, 1488:28-39.
63. Kita Y., Ohto T., Uozumi N., Shimizu T. Biochemical properties and pathophysiological roles of cytosolic phospholipase A2s. Biochim. Biophys. Acta 2006, 1761:1317-1322.
64. Calder P.C. Mechanisms of action of (n-3) fatty acids. J. Nutr. 2012, 142:592S-599S.